Skip to main content

Free Content Computational Insights into Binding of Bisphosphates to Farnesyl Pyrophosphate Synthase

Download Article:
(PDF 998.076171875 kb)


Bisphosphonates (BPs) are the most widely used and effective treatment for osteoporosis and Paget's disease. Non-nitrogen containing BPs (non-N-BPs), namely etidronate, clodronate, tiludronate, as well as nitrogen-containing BPs (N-BPs), namely pamidronate, alendronate, ibandronate, risedronate, zoledronate and minodronate have been launched on the market to date. N-BPs act by inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS), and several crystal structures of complexes between FPPS and N-BPs have been revealed. Understanding the physical basis of the binding between protein and small molecules is an important goal in both medicinal chemistry and structural biology. In this review, we analyze in detail the energetic basis of molecular recognition between FPPS and N-BPs. First, we summarize the interactions between ligands and proteins observed in N-BPs-FPPS complexes in the Protein Data Bank (PDB). Second, we present an interaction energy analysis on the basis of full quantum mechanical calculation of FPPS and N-BP complexes using the fragment molecular orbital (FMO) method. The FMO result revealed that not only hydrogen bond and electrostatic interaction but also CH-O and -interaction with FPPS are important for N-BP's potency. Third, we describe a binding site analysis of FPPS on the basis of the inhomogeneous solvation theory which, by clustering the results from an explicit solvent molecular dynamics simulation (MD), is capable of describing the entropic and enthalpic contributions to the free energies of individual hydration sites. Finally, we also discuss the structure-activity relationship (SAR) of the series of minodronate derivatives.

Keywords: Bisphosphonate; Bisphosphonates (BPs); Charge transfer plus higher-order mixed terms; Farnesyl Pyrophosphate Synthase; Geranyl Pyrophosphate; Isopentenyl Pyrophosphate; Isothermal titration calorimetry; Minodronic acid; Nitrogen-containing BPs; Paget's disease; Protein Data Bank; adenosine triphosphate; alendronate; antiresoptive activity; bone resorption; dispersion; drug design; electrostatic; enthalpy-driven; farnesyl pyrophosphate synthase; fragment molecular; ibandronate; ibandronate model; imidazopyrizine; isopentenyl pyrophosphate; isoprenyl synthases; isothermal titration calorimetry; mevalonate pathway; minodronate; osteoclast; osteoporosis; pamidronate; protein-ligand binding; quantum mechanics; risedronate; tiludronate; zoledronate

Document Type: Research Article


Publication date: 2011-01-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more